Fact CheckerSign in

NCT07193901CompletedPhase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior

A Randomized, Double-blind, Placebo-controlled Phase Il Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior

Source: ClinicalTrials.gov · Last updated 9 Sept 2026

Brief summary (registry, in English)

The purpose of this study is to learn about: * To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior * To evaluate the safety and pharmacokinetic (PK) characteristics after multiple dose of PRT-042 nasal spray in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
98 (actual)
First submitted
1 Sept 2025
Start date
27 May 2025
Primary completion date
10 Apr 2026
Lead sponsor
Sichuan Purity Pharmaceutical Technology Co., Ltd.
Diseases
Depression
NCT number
NCT07193901

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 98
  • From 27 May 2025 to the primary completion date, 10 Apr 2026
  • 15 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features .
  • Participant meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder, within the 6 months before screening
  • Participant has a current or prior diagnosis of a reatment resistant depression
  • Previous participation in another clinical trial and receiving the investigational drug within 3 months prior to dosing.

Other illness

  • Participant has a current DSM-5 diagnosis of bipolar (or related disorders), antisocial personality disorder, or obsessive compulsive disorder.
  • Participant has a current clinical diagnosis of autism, dementia, or intellectual disability.
  • Any nasal conditions or diseases that, in the investigator's judgment, may significantly affect the administration or absorption of a nasal product.
  • Participant has a history of malignancy within 5 years before screening

Other

  • Pregnant or breastfeeding women, or those with a positive pregnancy test result during screening.

Who the study is looking for

  • Participant must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) diagnostic criteria for Major Depressive Disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI) .
  • Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 \[Think (even momentarily) about harming or of hurting or of injuring yourself: with at least some intent or awareness that you might die as a result; or think about suicide (ie, about killing yourself)?\] and Question B10 \[Intend to act on thoughts of killing yourself?\] obtained from the MINI.
  • Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of greater than (≥) 28 and the score for item 10"suicide ideation" of greater than (≥) 3 predose on Day 1

Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (15)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The Sixth Hospital of Peking University
Coordinator of this site? Confirm its status
BeijinChinaUnknown status
Beijing Anding Hospital, Capital Medical University
Coordinator of this site? Confirm its status
BeijingChinaUnknown status
Beijing Huilongguan Hospital
Coordinator of this site? Confirm its status
BeijingChinaUnknown status
Brain Hospital of Hunan Province
Coordinator of this site? Confirm its status
ChangshaChinaUnknown status
The Second Xiangya Hospital of Central South University
Coordinator of this site? Confirm its status
ChangshaChinaUnknown status
The Fourth People's Hospital of Chengdu
Coordinator of this site? Confirm its status
ChengduChinaUnknown status
Hangzhou Seventh People's Hospital
Coordinator of this site? Confirm its status
HangzhouChinaUnknown status
The fourth affiliated hospital of Anhui medical university
Coordinator of this site? Confirm its status
HefeiChinaUnknown status
Hefei Fourth People's Hospital(Anhui Mental Health Prevention and Treatment Center)
Coordinator of this site? Confirm its status
HefeiChinaUnknown status
The Affiliated Hospital of Southwest Medical University
Coordinator of this site? Confirm its status
LuzhouChinaUnknown status
The First Affiliated Hospital of NanChang University
Coordinator of this site? Confirm its status
NanchangChinaUnknown status
The Affiliated Kangning Hospital of Ningbo University
Coordinator of this site? Confirm its status
NingboChinaUnknown status
Suzhou Guangji Hospital
Coordinator of this site? Confirm its status
SuzhouChinaUnknown status
Wuxi Mental Health Center
Coordinator of this site? Confirm its status
WuxiChinaUnknown status
Zhumadian Second People's Hospital(Zhumadian Psychiatric Hospital )
Coordinator of this site? Confirm its status
ZhumadianChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.